Cellular and Molecular Life Sciences · 2024 · 14 citations · 32 references
Life SciencesBiochemistryCardiologyCell SignalingPathophysiologySignal TransductionCardiac PhysiologyCardiovascular DiseaseCardiovascular Molecular PhysiologyCardiovascular PathophysiologyCardiovascular PhysiologyHeart FailureAdrenergic Receptor SignalingCalcium-calmodulin SignalingCalcium-dependent Protein Kinase IiCalmodulin-dependent Protein Kinase IiCardiac PathologyCardiac RemodelingCellular HypertrophyHeart Failure Molecular Mechanisms
Prolonged stimulation of β-adrenergic receptor (β-AR) can lead to sympathetic overactivity that causes pathologic cardiac hypertrophy and fibrosis, ultimately resulting in heart failure. Recent studies suggest that abnormal protein ubiquitylation may contribute to the pathogenesis of cardiac hypertrophy and remodeling. In this study, we demonstrated that deficiency of a deubiquitinase, Josephin domain-containing protein 2 (JOSD2), ameliorated isoprenaline (ISO)- and myocardial infarction (MI)-induced cardiac hypertrophy, fibrosis, and dysfunction both in vitro and in vivo. Conversely, JOSD2 overexpression aggravated ISO-induced cardiac pathology. Through comprehensive mass spectrometry analysis, we identified that JOSD2 interacts with Calcium-calmodulin-dependent protein kinase II (CaMKIIδ). JOSD2 directly hydrolyzes the K63-linked polyubiquitin chains on CaMKIIδ, thereby increasing the phosphorylation of CaMKIIδ and resulting in calcium mishandling, hypertrophy, and fibrosis in cardiomyocytes. In vivo experiments showed that the cardiac remodeling induced by JOSD2 overexpression could be reversed by the CaMKIIδ inhibitor KN-93. In conclusion, our study highlights the role of JOSD2 in mediating ISO-induced cardiac remodeling through the regulation of CaMKIIδ ubiquitination, and suggests its potential as a therapeutic target for combating the disease. Please check and confirm that the authors and their respective affiliations have been correctly identified and amend if necessary. All have been checked.
32
Diabetic hyperglycaemia activates CaMKII and arrhythmias by O-linked glycosylation
Jeffrey R. Erickson, Laëtitia Pereira, Lianguo Wang et al. · Nature · 2013 · 595 citations
Calmodulin kinase II inhibition protects against structural heart disease
Rong Zhang, Michelle S.C. Khoo, Yuejin Wu et al. · Nature Medicine · 2005 · 571 citations
Medicine, Biochemistry, Pharmacology +14
Oxidation of CaMKII determines the cardiotoxic effects of aldosterone
B. Julie He, Mei-ling A. Joiner, Madhu V. Singh et al. · Nature Medicine · 2011 · 237 citations · Full text